All In Biotech

Drug Trial Radar · NCT02256436

A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045)

A Phase III Randomized Clinical Trial of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel or Vinflunine in Subjects With Recurrent or Progressive Metastatic Urothelial Cancer

Last checked: Nov 19, 2026Latest source record: Sep 20, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 542 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

542

Actual

Start

Oct 22, 2014

Primary completion

Sep 7, 2016

Study completion Oct 1, 2020

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Oct 3, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Participants with metastatic or locally advanced/unresectable urothelial cancer that has recurred or progressed following platinum-based chemotherapy will be randomly assigned to receive Investigator's choice of paclitaxel, docetaxel, or vinflunine (Control), or pembrolizumab. The primary study hypotheses are that pembrolizumab will prolong Overall Survival (OS) and Progression-free Survival (PFS) compared to paclitaxel, docetaxel, or vinflunine.

Conditions

  • Urothelial Cancer

Interventions

  • pembrolizumabBiological

    IV infusion

  • paclitaxelDrug

    IV infusion

  • vinflunineDrug

    IV infusion

  • docetaxelDrug

    IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) - All ParticipantsTime frame: Through primary analysis database cut-off date of 07-Sep-2016 (Up to approximately 20 months)
  2. Overall Survival (OS) - All ParticipantsTime frame: Through primary analysis database cut-off date of 07-Sep-2016 (Up to approximately 20 months)
  3. PFS Per RECIST 1.1 - Participants With Programmed Cell Death-Ligand (PD-L1) Positive TumorsTime frame: Through primary analysis database cut-off date of 07-Sep-2016 (Up to approximately 20 months)
  4. OS - Participants With PD-L1 Positive TumorsTime frame: Through primary analysis database cut-off date of 07-Sep-2016 (Up to approximately 20 months)
  5. PFS Per RECIST 1.1 - Participants With Strongly PD-L1 Positive TumorsTime frame: Through primary analysis database cut-off date of 07-Sep-2016 (Up to approximately 20 months)
  6. OS - Participants With Strongly PD-L1 Positive TumorsTime frame: Through primary analysis database cut-off date of 07-Sep-2016 (Up to approximately 20 months)

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.